Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.
Penetration of teicoplanin into serum, heart valves, and subcutaneous and muscle tissues was determined in 22 patients undergoing open-heart surgery. Each patient received 12 mg of teicoplanin per kg of body weight as a 30-min intravenous infusion preoperatively. Within 10 h, serum concentrations of teicoplanin declined from 43.1 to 2.8 microg/ml. Teicoplanin concentrations in subcutaneous tissues reached their peak of 9.2 microg/g after 2 to 3 h and decreased slowly to 2.3 microg/g after 9 to 10 h. Concentrations in muscle decreased from 8.7 microg/g to nondetectable levels. Teicoplanin concentrations in cardiac valvular tissue reached their peak of 6.1 microg/g and decreased thereafter to 1.7 microg/g. Teicoplanin concentrations in heart valves were high enough to inhibit methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci, which are known to cause postoperative wound infections and infective endocarditis.
Frank
U K
UK
Institute for Environmental Medicine and Hospital Epidemiology, University Hospital Freiburg, Germany.
Schmidt-Eisenlohr
E
E
Mlangeni
D
D
Schindler
M
M
Hoh
A
A
Beyersdorf
F
F
Daschner
F D
FD
D000368:Aged; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D005260:Female; D006351:Heart Valves / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009131:Muscle, Smooth, Vascular / Q000378:metabolism; D017334:Teicoplanin / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D013903:Thoracic Surgery; D014018:Tissue Distribution
D000900:Anti-Bacterial Agents; D017334:Teicoplanin